A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti_Tumor Activity of AVZO-021 as a Single Agent and in Combination Therapy in Patients with Advanced Solid Tumors.

Status

Not yet recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517339-30-00

Acronym

AVZO-021-1001

Enrollment

Registered

2025-03-03

Start date

Unknown

Completion date

Unknown

Last updated

2025-12-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Solid Tumors

None listed

Sex/Gender

All

Age

18 Years to No maximum

Belgium, France, Germany, Italy, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026